Table of Contents
Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on Dyslipidaemia (Familial Type) in 8 Major Markets
Dyslipidaemia is defined as individuals with elevated triglycerides, low density lipoprotein or total cholesterol, or with lowered levels of high density lipoprotein. Many patients meet the requirements of Dyslipidaemia on more than one factor.
Dyslipidaemia can be divided into two forms: familial (primary) or acquired (secondary). Primary causes are single or multiple gene mutations and secondary causes are mainly a result of a sedentary lifestyle, with diets that consist largely of saturated fats, cholesterol and trans-fats.
This report provides the current prevalent population for Dyslipidaemia, with primary focus on the familial/primary type, across 8 Major Markets (USA, France, Germany, Italy, Spain, UK, Brazil and Japan) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.
Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Familial Dyslipidaemia have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.
Main symptoms and co-morbidities for Dyslipidaemia include:
-Diabetes & metabolic syndrome
-Coronary artery disease
-Peripheral arterial disease
-Aortic stenosis (familial)
This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.
Reason to buy
-Able to quantify patient populations in global Dyslipidaemia’s market to target the development of future products, pricing strategies and launch plans.
-Gain further insight into the prevalence of the subdivided types of Dyslipidaemia and identify patient segments with high potential.
-Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
-Provide a level of understanding on the impact from specific co-morbid conditions on Dyslipidaemia’s prevalent population.
-Identify sub-populations within Dyslipidaemia which require treatment.
-Gain an understanding of the specific markets that have the largest number of Dyslipidaemia patients.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
Pipeline Overview Idiopathic pulmonary fibrosis (IPF) is referred to as progressive and chronic interstitial pneumonia without known cause. Pulmonary fibrosis is a disease in which tissue profound in lungs ...
Chronic Kidney Disease (CKD) Drugs Market (Drug Class - ACE Inhibitors, Angiotensin-II Receptor Blockers, Calcium Channel Blockers, Beta Blockers, Erythropoiesis - stimulating Agents (ESAs), and Diuretics; ...
The global cholesterol testing services market is expected to reach USD 17.5 billion by 2021 from USD 11.9 billion in 2016, growing at a CAGR of 8% during the forecast period. This market is segmented ...